Finance

Lists
Why is GRF up 2,02%?
Dive Deeper
GRF:BME
Grifols SA Class A
9,88 €
+2,02%
(+0,20) 1D
9 հոկ, 17:36:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for GRF...
Open
9,79 €
High
10,00 €
Low
9,78 €
Mkt. cap
5,90 մլրդ
Avg. vol.
1,20 մլն
Volume
1,43 մլն
Dividend
2,35%
Quarterly dividend
0,06 €
Ex-dividend date
30 հնս, 2026 թ.
P/E ratio
14,86
52-wk high
12,32 €
52-wk low
8,43 €
EPS
0,67 €
Shares outstanding
426,13 մլն
No. of employees
25 հզր
Open
9,79 €
High
10,00 €
Low
9,78 €
Mkt. cap
5,90 մլրդ
Avg. vol.
1,20 մլն
Volume
1,43 մլն
Dividend
2,35%
Quarterly dividend
0,06 €
Ex-dividend date
30 հնս, 2026 թ.
P/E ratio
14,86
52-wk high
12,32 €
52-wk low
8,43 €
EPS
0,67 €
Shares outstanding
426,13 մլն
No. of employees
25 հզր
News stories
From web sources and news partners
Profile
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30. Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
About Grifols SA Class A
CEONacho Abia
Employees25 հզր
Founded18 նոյ, 1940 թ.
Headquarters-
Sector-
Last report
28 հլս, 2026 թ.
Fiscal period
Q2 2026
- / 0,24 €
Revenue / Est. (EUR)
1,87 մլրդ / 1,89 մլրդ
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
1,87 մլրդ
1,98 մլրդ
1,70 մլրդ
1,87 մլրդ
Cost of goods sold
1,11 մլրդ
1,28 մլրդ
1,06 մլրդ
1,19 մլրդ
Cost of revenue
1,11 մլրդ
1,28 մլրդ
1,06 մլրդ
1,19 մլրդ
Research and development expenses
97,01 մլն
90,82 մլն
90,00 մլն
86,00 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
273,76 մլն
262,86 մլն
269,00 մլն
301,00 մլն
Operating expense
370,34 մլն
353,11 մլն
359,00 մլն
387,00 մլն
Total operating expenses
1,48 մլրդ
1,63 մլրդ
1,42 մլրդ
1,58 մլրդ
Operating income
381,18 մլն
347,38 մլն
280,00 մլն
298,00 մլն
Other non operating income
-
-33,00 մլն
-
-13,00 մլն
EBT including unusual items
198,13 մլն
111,10 մլն
112,00 մլն
247,00 մլն
EBT excluding unusual items
227,20 մլն
183,10 մլն
143,00 մլն
216,00 մլն
Income tax expense
54,71 մլն
-14,68 մլն
24,00 մլն
64,00 մլն
Effective tax rate
27,61%
-13,21%
21,43%
25,91%
Other operating expenses
-430,00 հզր
-570,00 հզր
-
-
Net income
126,96 մլն
98,25 մլն
73,00 մլն
154,00 մլն
Net profit margin
6,81%
4,96%
4,29%
8,22%
Earnings per share
-
-
-
-
Interest and investment income
-
36,00 մլն
-
120,00 մլն
Interest expense
-156,07 մլն
-107,99 մլն
-139,00 մլն
-179,00 մլն
Net interest expenses
-156,07 մլն
-71,99 մլն
-139,00 մլն
-59,00 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
484,03 մլն
422,88 մլն
384,00 մլն
364,00 մլն
Gain or loss from assets sale
-
2,00 մլն
-
-6,00 մլն
AI content may include mistakes. Learn more
Google Apps